Every material Form 8-K Paysign, Inc. has filed with the SEC since March 24, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Paysign reported third-quarter 2026 revenue of $30.80 million, up 42.6%, and GAAP net income of $6.74 million, or $0.11 per diluted share, versus $0.04 a year earlier. The company raised its full-year 2026 net income, diluted EPS and Adjusted EBITDA guidance and confirmed its revenue outlook, but a plasma customer's decision to move processing for 113 centers will reduce fourth-quarter results.
Q3 2026 revenue was $30.80 million, up 42.6%; pharma revenue rose 109.8% to $16.62 million, and plasma revenue rose 7.5% to $13.83 million.
GAAP net income was $6.74 million, or $0.11 per diluted share, versus $2.22 million, or $0.04 per diluted share, in Q3 2025.
Full-year 2026 guidance: net income $23.0 million to $24.0 million, diluted EPS $0.37 to $0.38, Adjusted EBITDA $38.5 million to $40.0 million; revenue outlook of $114.0 million to $117.0 million was confirmed.
A plasma customer will move payment processing for 113 centers to another provider by year-end; the estimated Q4 impact is $1.5 million in revenue and $700 thousand in gross profit.
Paysign reported second-quarter 2026 revenue of $28.25 million, up 48.1% from a year earlier, and net income of $6.76 million, or $0.11 per diluted share, versus $1.39 million, or $0.02, in the prior-year quarter. The company raised its full-year 2026 outlook to revenue of $114.0 million to $117.0 million and Adjusted EBITDA of $35.0 million to $38.0 million. Net income includes a one-time, non-cash $990,000 fair value gain on contingent consideration tied to the Gamma acquisition.
Q2 2026 revenue of $28.25 million, up 48.1%; pharma revenue up 88.9% to $14.65 million, plasma revenue up 21.4% to $13.04 million
Net income of $6.76 million, or $0.11 per diluted share, versus $1.39 million, or $0.02, in Q2 2025
Full-year 2026 outlook raised: revenue $114.0 million to $117.0 million; Adjusted EBITDA $35.0 million to $38.0 million
Plasma center count fell by 46 over 12 months to 561; company exited quarter with $27.37 million unrestricted cash and zero bank debt
Paysign reported first-quarter 2026 revenue of $28.04 million, up 50.8% from a year earlier, and net income of $5.44 million, or $0.09 per diluted share, up 110.3% from $2.59 million. The company reiterated its full-year 2026 revenue guidance of $106.5 million to $110.5 million, and said it expects to finish in the upper half of its guidance ranges.
Q1 2026 revenue of $28.04 million, up from $18.6 million in Q1 2025; pharma revenue rose 81.9% to $15.68 million.
Net income of $5.44 million, or $0.09 per diluted share, versus $2.59 million, or $0.05 per diluted share, in Q1 2025.
Full-year 2026 guidance reiterated: revenue of $106.5 million to $110.5 million and diluted EPS of $0.21 to $0.26; Q2 2026 revenue guidance is $26.2 million to $26.7 million.
Unrestricted cash was $20.55 million at March 31, 2026, with zero bank debt.
Paysign reported full-year 2025 revenue of $82.0 million, up 40.5%, and net income of $7.55 million, or $0.13 per diluted share, compared with $3.82 million, or $0.07, in 2024. The company also projected 2026 revenue of $106.5 million to $110.5 million and net income of $13.0 million to $16.0 million, with growth attributed mainly to its patient affordability business. Fourth-quarter 2025 net income of $1.36 million was down 0.8% from the prior-year quarter.
Full-year 2025 revenue was $82.0 million, up from $58.4 million in 2024.
Full-year 2025 net income was $7.55 million, or $0.13 per diluted share, versus $3.82 million, or $0.07, in 2024.
Q4 2025 net income was $1.36 million, down 0.8% from $1.37 million in Q4 2024.
2026 guidance: revenue of $106.5 million to $110.5 million and net income of $13.0 million to $16.0 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Paysign, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →